source
- Incyte agrees to acquire Vega Therapeutics for $1.25 billion upfrontIncyte announced it will purchase Vega Therapeutics, a subsidiary of Star Therapeutics, in a transaction that includes an upfront payment of $1.25 billion. The acquisition gives Incyte control of…
- City Therapeutics secures $99.5 million to advance RNAi drugs targeting clotting disorder and Stargardt diseaseCity Therapeutics, a young biotech focused on RNA interference therapies, announced it has raised $99.5 million to support further development of its pipeline. The funding will back its lead candid…